#United States #Los Angeles #Securities Law #DJS Law Group #Capricor

Capricor Therapeutics Sued for Securities Law Violations

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is facing significant legal challenges as a class action lawsuit has been filed against the company, centered around alleged violations of federal securities laws. This lawsuit highlights the serious implications for investors and shareholders who have been impacted by the company's purported misconduct.

Overview of the Lawsuit

On September 8, 2026, DJS Law Group announced the initiation of the lawsuit, reminding investors that if they bought shares of Capricor between December 17, 2025, and July 26, 2026, they are encouraged to engage with the firm regarding potential lead plaintiff roles. Importantly, individuals do not need to be appointed as lead plaintiffs to recover damages through this suit.

The crux of the allegations lies in Capricor's alleged failure to disclose critical changes in its clinical trial processes. The complaint states that the company modified the statistical analysis plan for analyzing clinical data related to its drug, Deramiocel, without the necessary approvals from the FDA before resubmitting its Biologics License Application (BLA). Consequently, the lawsuit asserts that the company's public statements during the outlined class period were misleading and materially false.

How This Affects Investors

The implications of such allegations are severe for current and former shareholders of Capricor. The purported misleading information shared by the company could have led many investors to make decisions based on incomplete and inaccurate data, which may have resulted in financial losses. Those affected are urged to reach out to the DJS Law Group to discuss their options, as the deadline for filing claims is September 28, 2026.

Why Choose DJS Law Group?

With experience in securities class actions and corporate governance litigation, DJS Law Group positions itself as a strong advocate for investor rights. The firm serves a clientele that includes prominent hedge funds and alternative asset managers, emphasizing their commitment to maximizing shareholder recovery in such lawsuits. David Schwartz, a founding partner at DJS Law Group, has specialized in navigating complex legal terrains, making the firm a pivotal player in this case.

Investors who believe they have suffered losses due to the alleged actions of Capricor are encouraged to come forward and participate in the legal proceedings. Engaging with a law firm experienced in these matters can provide potential avenues for claiming back losses attributable to the company's conduct.

In conclusion, the unfolding situation surrounding Capricor Therapeutics serves as a crucial reminder of the importance of transparency in business operations, especially within the biotech sector. For shareholders, it highlights the need for vigilance and awareness regarding company communications and the impact they can have on investment decisions. If you or someone you know has been affected, do not hesitate to seek legal counsel and hold corporations accountable for their actions.

Conclusion

As the case develops, all eyes will be on how Capricor Therapeutics responds to these serious allegations and what measures they will implement to address investor concerns. The outcome of this lawsuit could have far-reaching implications not only for the company and its shareholders but also for broader discussions on corporate ethics and accountability within the pharmaceutical industry.